The premises and/or the manufacturing process were inadequate for minimizing contamination of the drugs and/or materials during fabrication and/or packaging.
Inspection Record
AbbVie Inc. — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Investigations into deviations, reports, and/or follow-up actions were inadequate.
The sanitation programs were not adequately designed to identify and/or reduce the risks of contamination. The equipment was not set-up, designed, operated, stored, and/or maintained to prevent potential contamination of drugs by other drugs and/or by foreign material.
The traceability, legibility, documentation, formatting, and/or the accuracy of records was inadequate. The recorded information or details were inadequate.
The suitability of the culture media was not verified.
Evaluation of production processes, equipment, and/or materials was inadequate.
The equipment was not set-up, designed, operated, stored, and/or maintained to prevent potential contamination of drugs by other drugs and/or by foreign material. The preventative maintenance program was inadequate for the equipment used in significant processing and/or testing operations.
The sanitation programs were not adequately designed to identify and/or reduce the risks of contamination.
About this record
Extracted automatically from the document of the Health Canada inspection on 2022-06-13. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
